These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37977850)

  • 1. The potential future role of extensive lipid lowering in ACS patients with the use of PCSK9 inhibitors: early bird catches the worm.
    Dimitriadis K; Pyrpyris N; Tsioufis K
    Eur Heart J Cardiovasc Pharmacother; 2024 Feb; 10(2):85-86. PubMed ID: 37977850
    [No Abstract]   [Full Text] [Related]  

  • 2. First-in-human gene editing for lipid lowering: the initial results.
    Tual-Chalot S; Stellos K
    Cardiovasc Res; 2024 Mar; 120(4):e5-e8. PubMed ID: 38554379
    [No Abstract]   [Full Text] [Related]  

  • 3. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
    Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
    BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in Patient Access to and Utilization of Prescribed PCSK9 Inhibitors in a Large US Claims Database From 2015 to 2021.
    MacDougall DE; Baum SJ; Ahmed CD; McGowan MP; Wilemon KA
    Circ Cardiovasc Qual Outcomes; 2024 Feb; 17(2):e009988. PubMed ID: 38362767
    [No Abstract]   [Full Text] [Related]  

  • 5. [Not Available].
    Einecke D
    MMW Fortschr Med; 2024 May; 166(8):18. PubMed ID: 38693368
    [No Abstract]   [Full Text] [Related]  

  • 6. PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance.
    Jia X; Al Rifai M; Saeed A; Ballantyne CM; Virani SS
    Vasc Health Risk Manag; 2022; 18():555-566. PubMed ID: 35898405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction.
    Schwartz GG; Giugliano RP
    Curr Opin Lipidol; 2022 Jun; 33(3):147-159. PubMed ID: 35695614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proprotein Convertase Subtilisin Kexin-9 Inhibitors (PCSK9i) in Atherosclerotic Cardiovascular Disease: Real-World Data Welcome.
    Moroni F; Ayers MP; Dixon DL; Abbate A
    J Cardiovasc Pharmacol; 2023 May; 81(5):336-338. PubMed ID: 37043382
    [No Abstract]   [Full Text] [Related]  

  • 9. Lipid-lowering therapies in peripheral artery disease: A review.
    Skeik N; Nowariak ME; Smith JE; Alexander JQ; Manunga JM; Mirza AK; Sullivan TM
    Vasc Med; 2021 Feb; 26(1):71-80. PubMed ID: 33074778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCSK9 inhibitors and reduction in cardiovascular events: Current evidence and future perspectives.
    Nicholls SJ
    Kardiol Pol; 2023; 81(2):115-122. PubMed ID: 36739653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of early in-hospital use of PCSK9 inhibitors on cardiovascular outcomes in acute coronary syndrome patients: A systematic review and meta-analysis.
    Yifan D; Yue M; Yubin Z; Jiapei G; Xun S; Shenghu H; Li Z; Jing Z
    Int J Cardiol; 2024 Mar; 399():131775. PubMed ID: 38211676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors.
    Nelson CP; Lai FY; Nath M; Ye S; Webb TR; Schunkert H; Samani NJ
    Circ Genom Precis Med; 2019 Jan; 12(1):e002196. PubMed ID: 30645167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world lipid lowering effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: A single-centre study.
    Han J; Bilgrami S; Ross S; Broadhead H; Attar N
    Int J Cardiol; 2021 Jan; 322():240-244. PubMed ID: 32827563
    [No Abstract]   [Full Text] [Related]  

  • 14. In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?
    Canonico ME; Hess CN; Cannon CP
    Curr Atheroscler Rep; 2023 Jul; 25(7):381-389. PubMed ID: 37223853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network.
    Chamberlain AM; Gong Y; Shaw KM; Bian J; Song WL; Linton MF; Fonseca V; Price-Haywood E; Guhl E; King JB; Shah RU; Puro J; Shenkman E; Pawloski PA; Margolis KL; Hernandez AF; Cooper-DeHoff RM
    J Am Heart Assoc; 2019 May; 8(9):e011246. PubMed ID: 31020929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein(a) lowering and cardiovascular risk reduction by PCSK9 inhibitors.
    Safarova MS; Kullo IJ
    Atherosclerosis; 2022 Nov; 361():30-31. PubMed ID: 36344291
    [No Abstract]   [Full Text] [Related]  

  • 18. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety.
    Roth EM; Davidson MH
    Rev Cardiovasc Med; 2018; 19(S1):S31-S46. PubMed ID: 30207556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged and Pronounced Low-Density Lipoprotein Cholesterol Lowering: The Gift That Keeps Giving.
    Shapiro MD
    Circulation; 2022 Oct; 146(15):1120-1122. PubMed ID: 36031845
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.